CVAC - CureVac N.V.
After hours:
| Previous close | 9.43 |
| Open | 9.47 |
| Bid | 9.02 x 800 |
| Ask | 9.18 x 900 |
| Day's range | 9.06 - 9.49 |
| 52-week range | 5.63 - 19.67 |
| Volume | |
| Avg. volume | 534,582 |
| Market cap | 2.048B |
| Beta (5Y monthly) | 2.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.38 |
| Earnings date | 29 May 2023 - 30 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.38 |
Simply Wall St.CureVac N.V.'s (NASDAQ:CVAC) market cap surged US$362m last week, private equity firms who have a lot riding on the company were rewarded
Key Insights CureVac's significant private equity firms ownership suggests that the key decisions are influenced by...
ReutersCureVac files expanded patent lawsuit against Pfizer/BioNTech over mRNA technology
The company said it filed a counterclaim alleging that Pfizer and its German partner BioNTech infringed on nine of its patents, broader than its original claim of three patents. In July 2022, CureVac had filed a patent lawsuit against BioNTech over the use of mRNA technology in the companies' COVID-19 vaccine. The transfer of the trial to the Eastern District of Virginia from the Federal District Court of Massachusetts is expected to accelerate progress of the case and allow for a likely 2024 trial date, CureVac said on Friday.
- EQS Group
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Issuer: CureVac / Key word(s): Patent/Legal Matter19.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly relevant
- EQS Group
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Issuer: CureVac / Key word(s): Study08.05.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens
- Simply Wall St.
Analyst Forecasts Just Became More Bearish On CureVac N.V. (NASDAQ:CVAC)
One thing we could say about the analysts on CureVac N.V. ( NASDAQ:CVAC ) - they aren't optimistic, having just made a...
- EQS Group
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
Issuer: CureVac / Key word(s): Quarterly / Interim Statement25.04.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint Early 2023, strong validation of CureVac’s proprietary mRNA technology
- EQS Group
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
Issuer: CureVac / Key word(s): Quarterly / Interim Statement18.04.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023 TÜBINGEN, Germany/ BOSTON, USA – April 18, 2023 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results,
- Simply Wall St.
CureVac N.V.'s (NASDAQ:CVAC) Shares May Have Run Too Fast Too Soon
With a price-to-sales (or "P/S") ratio of 16.2x CureVac N.V. ( NASDAQ:CVAC ) may be sending bearish signals at the...
- EQS Group
CureVac Announces Voting Results of Extraordinary General Meeting
Issuer: CureVac / Key word(s): AGM/EGM28.03.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Voting Results of Extraordinary General Meeting TÜBINGEN, Germany / BOSTON, USA – March 28, 2023 – CureVac N.V. (Nasdaq: CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the voting results of the Company's extraordinary genera
- Simply Wall St.
As CureVac N.V.'s market cap (NASDAQ:CVAC) drops to US$1.4b, insiders might be questioning their decision to buy earlier this year
The recent 7.1% drop in CureVac N.V.'s ( NASDAQ:CVAC ) stock could come as a blow to insiders who purchased €97m worth...
- Simply Wall St.
The past year for CureVac (NASDAQ:CVAC) investors has not been profitable
While it may not be enough for some shareholders, we think it is good to see the CureVac N.V. ( NASDAQ:CVAC ) share...
- EQS Group
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
Issuer: CureVac / Key word(s): Financing10.02.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 10, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the closing of its follow-on public o
- EQS Group
CureVac Announces Pricing of Upsized Public Offering of Common Shares
Issuer: CureVac / Key word(s): Financing08.02.2023 / 02:03 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Pricing of Upsized Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 7, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today the pricing of 27,027,028 common shares in an underwr
- EQS Group
CureVac Announces Proposed Public Offering of Common Shares
Issuer: CureVac / Key word(s): Financing06.02.2023 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Proposed Public Offering of Common Shares TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its common shares in a
- EQS Group
CureVac Welcomes Myriam Mendila as New Chief Development Officer
Issuer: CureVac / Key word(s): Personnel01.02.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Welcomes Myriam Mendila as New Chief Development Officer Dr. Mendila joins CureVac as Chief Development Officer with more than 20 years of global industry experienceTÜBINGEN, Germany/ BOSTON, USA – February 1, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribo
- EQS Group
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®
Issuer: CureVac / Key word(s): Patent31.01.2023 / 14:12 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis® CureVac recognized as a Top 100 innovator in acknowledgment of the company’s innovative strength and extensive intellectual property portfolio The company holds one of broadest intellectual property portfolios in mRNA technologyTÜBINGEN, Germany/ BOSTON, USA – January 31, 2023 – CureVac N.V
- EQS Group
CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)
Issuer: CureVac / Key word(s): Study30.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants i
Motley FoolWhy CureVac's Shares Jumped on Tuesday
Shares of CureVac (NASDAQ: CVAC) rose as much as 19.1% on Tuesday. Despite the rise, CureVac is down more than 59% over the past year, though it is now up more than 61% over the past three months. Investors continued to flock to the healthcare stock after the biotech announced late Friday that several of its messenger RNA vaccines were doing well in early trials.
- EQS Group
CureVac Appoints Alexander Zehnder as CEO From April 1, 2023
Issuer: CureVac / Key word(s): Personnel09.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Appoints Alexander Zehnder as CEO From April 1, 2023 Dr. Franz-Werner Haas to complete successful tenure as CEO by March 31, 2023 Dr. Alexander Zehnder to succeed Dr. Haas as new CEO, joining from Sanofi on April 1, 2023TÜBINGEN, Germany/ BOSTON, USA – January 9, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new cla
- Simply Wall St.
CureVac N.V. (NASDAQ:CVAC) Shares Could Be 46% Below Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of CureVac N.V. ( NASDAQ:CVAC ) by projecting its future...
- EQS Group
CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs
Issuer: CureVac / Key word(s): Interim Report/Study06.01.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs Promising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac’s advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and stro
- EQS Group
CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive Program
Issuer: CureVac / Key word(s): Transaction in Own Shares14.12.2022 / 22:05 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Members of Management Sell Shares to Cover Tax Obligations fromLong Term Incentive Program TÜBINGEN, Germany/ Boston, USA – December 14, 2022 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Chief Executi
- Simply Wall St.
Private equity firms are CureVac N.V.'s (NASDAQ:CVAC) biggest owners and were hit after market cap dropped US$101m
To get a sense of who is truly in control of CureVac N.V. ( NASDAQ:CVAC ), it is important to understand the ownership...
ZacksWall Street Analysts Believe CureVac N.V. (CVAC) Could Rally 139%: Here's is How to Trade
The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- EQS Group
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
Issuer: CureVac / Key word(s): Quarterly / Interim Statement16.11.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 St